Clinical trials

Procedures for Clinical Trials in the case of No-Deal-Brexit

For further information please click here.

Clinical trial statistics

The following document summarises statistics of clinical trials of the past years. The information will also be published in the uptodate-Newslater of the BASG in June.


Information on the submission of clinical trials, the approval procedure, fees and sponsor responsibilities during and after completion of a clinical trial is compiled in the "Guidance for CT submission".


Clinical trials require prior approval by the BASG (Federal Office for Safety in Health Care; Bundesamt für Sicherheit im Gesundheitswesen). The "List of Documentation Required" summarises the required dossier content.


The cited documents represent the translation of European guidance, which is found in the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1).


The submission to Austrian (Lead) Ethics committees is to occur prior or in parallel to the submission to the BASG.


An amendment might become necessary should the clinical trial be modified after approval. A tabulated summary of which amendments are considered as substantial and which as non-substantial with the BASG and Ethics committees is provided in the "Classification of Amendments".


For the actual fees applicable for clinical trials, please see the following link.


Should our guidance documents not answer your questions, please contact clinicaltrialsbasg.gvat


Dr. Stefan Strasser

Dr. Ilona Reischl


Created: 08.03.2009 | Page last modified: 03.07.2019

© Austrian Federal Office for Safety in Health Care
to top